Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 781 to 795 of 2188 results for guidelines

  1. Mortality: respiratory (IND281)

    This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  2. Evidence summaries: new medicines – Integrated process statement (PMG11)

    This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs

  3. Infections: scoring tools for sore throat (IND323)

    This indicator covers the percentage of diagnoses of sore throat in the preceding 12 months with a recorded FeverPain or Centor score. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  4. Modular updates

    Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.

  5. Ivabradine for treating chronic heart failure (TA267)

    Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.

  6. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds (MIB208)

    NICE has developed a medtech innovation briefing (MIB) on NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds .

  7. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

  8. Kidney conditions: CKD urine albumin:creatinine ratio (IND144)

    This indicator covers the percentage of patients on the CKD register whose notes have a record of a urine albumin:creatinine ratio (or protein:creatinine ratio) test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM109

  9. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date: TBC

  10. Bulevirtide for treating chronic hepatitis D (TA896)

    Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

  11. Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)

    NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma

  12. SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)

    Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.

  13. Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)

    Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.

  14. Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)

    NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care

  15. SEM Scanner 200 for preventing pressure ulcers (HTG556)

    Evidence-based recommendations on SEM Scanner 200 for preventing pressure ulcers.